please read this, page-4

Turbu+ device is the standard device that ADR have been making for Astra Zeneca for years. Looks like a study in Italy that has taken many years to recruit, possibly 5 based on the fact its says " Patients who had joined the Turbu+ program before November 11, 2018, and had been enrolled in the program for at least 90 days were included in the analysis." No new news here. Comfimation of the many academic research publications that the benefits of the device can be seen in a clinical population. How this can be extrapolated to a wider population at scale is the question everyone has been looking for. Be interesting to see what AZ do with this considering they have had access to this device in UK and Europe since around 2015 and to date have made little to no progress. Why - lack or reimbursement in UK and Europe. AZ have not approved this type of dry powder inhaler the US.